Cargando…

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants

HER-2 belongs to the human epidermal growth factor receptor (HER) family. Via different signal transduction pathways, HER-2 regulates normal cell proliferation, survival, and differentiation. Recently, it was reported that MCF10A, BT474, and MDA-MB-231 cells bearing the HER2 K753E mutation were resi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verma, Sharad, Goyal, Sukriti, Kumari, Anchala, Singh, Aditi, Jamal, Salma, Grover, Abhinav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794075/ https://www.ncbi.nlm.nih.gov/pubmed/29389942 http://dx.doi.org/10.1371/journal.pone.0190942

Ejemplares similares

Conformational Ensembles of α-Synuclein Derived Peptide with Different Osmolytes from Temperature Replica Exchange Sampling
por: Jamal, Salma, et al.
Publicado: (2017)

Alanine mutation of the catalytic sites of Pantothenate Synthetase causes distinct conformational changes in the ATP binding region
por: Pandey, Bharati, et al.
Publicado: (2018)

Hydrophobic Interactions Are a Key to MDM2 Inhibition by Polyphenols as Revealed by Molecular Dynamics Simulations and MM/PBSA Free Energy Calculations
por: Verma, Sharad, et al.
Publicado: (2016)

Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships
por: Goyal, Sukriti, et al.
Publicado: (2015)

Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease
por: Gupta, Ankita, et al.
Publicado: (2015)

Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs
por: Dholakia, Dhwani, et al.
Publicado: (2016)

Novel group-based QSAR and combinatorial design of CK-1δ inhibitors as neuroprotective agents
por: Joshi, Kopal, et al.
Publicado: (2016)

Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for Drug Repurposing
por: Jamal, Salma, et al.
Publicado: (2015)

Integrating network, sequence and functional features using machine learning approaches towards identification of novel Alzheimer genes
por: Jamal, Salma, et al.
Publicado: (2016)

Predicting neurological Adverse Drug Reactions based on biological, chemical and phenotypic properties of drugs using machine learning models
por: Jamal, Salma, et al.
Publicado: (2017)

Ameliorating amyloid aggregation through osmolytes as a probable therapeutic molecule against Alzheimer's disease and type 2 diabetes
por: Kumari, Anchala, et al.
Publicado: (2020)

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase
por: Jathal, Maitreyee K., et al.
Publicado: (2019)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Amyloid fibrillation of the glaucoma associated myocilin protein is inhibited by epicatechin gallate (ECG)
por: Sharma, Ritika, et al.
Publicado: (2022)

Correction: Amyloid fibrillation of the glaucoma associated myocilin protein is inhibited by epicatechin gallate (ECG)
por: Sharma, Ritika, et al.
Publicado: (2022)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Bleomycin modulates amyloid aggregation in β-amyloid and hIAPP
por: Kumari, Anchala, et al.
Publicado: (2020)

Mechanistic Insights into the Binding of Class IIa HDAC Inhibitors toward Spinocerebellar Ataxia Type-2: A 3D-QSAR and Pharmacophore Modeling Approach
por: Sinha, Siddharth, et al.
Publicado: (2017)

The polyphenolic phytoalexin polydatin inhibits amyloid aggregation of recombinant human prion protein
por: Sirohi, Preeti Rana, et al.
Publicado: (2021)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

Mechanistic insights into mode of action of novel natural cathepsin L inhibitors
por: Tyagi, Chetna, et al.
Publicado: (2013)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
por: Lee, Hye Jin, et al.
Publicado: (2020)

Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus
por: Grover, Sonam, et al.
Publicado: (2014)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
por: Ning, Gang, et al.
Publicado: (2021)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

In silico analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus
por: Jain, Jaspreet, et al.
Publicado: (2017)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib
por: Showalter, Loral E., et al.
Publicado: (2019)

Novel Natural Structure Corrector of ApoE4 for Checking Alzheimer's Disease: Benefits from High Throughput Screening and Molecular Dynamics Simulations
por: Goyal, Manisha, et al.
Publicado: (2013)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim
por: Park, Sun Hee, et al.
Publicado: (2015)

Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells
por: Kaczyńska, Angelika, et al.
Publicado: (2016)

Dynamic ultrasound molecular‐targeted imaging of senescence in evaluation of lapatinib resistance in HER2‐positive breast cancer
por: Chen, Xiaoyu, et al.
Publicado: (2023)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_q4d9tfsvm7il00t5h5fkdfgrtv